Current developments in Clostridioides difficile prevention, therapy, and R&D
Speaker Sessions
Moderated by Christian John Lillis, Chief Executive Officer, Peggy Lillis Foundation (USA)
Global epidemiology of C. Difficile and WHO priorities for prevention | Benedikt Huttner, Unit Head – Research, Access, Stewardship and AMR surveillance, Department of Antimicrobial Resistance, World Health Organization (Switzerland)
Pathophysiology of C difficile infection – implications for treatment | Paul Feuerstadt, Attending Physician, PACT Gastroenterology Center, Associate Clinical Professor of Medicine, Yale School of Medicine (USA)
Updates on diagnosis | Kerrie Davies, Consultant Clinical Scientist, NIHR Leeds Biomedical Research Center (UK)
Pipeline of new therapies | Mark Wilcox, Professor of Medical Microbiology, University of Leeds (UK)